EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Smita Scholtz, Volker Rudolph, Jan-Christian Reil

Journal of Clinical Medicine · 19.10.2023 · 12 (20) · 6628

DOI: 10.3390/jcm12206628 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.10.2023. Verfasst von Smita Scholtz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Klinik für Allgemeine und Interventionelle Kardiologie/Angiologie, Herz und Diabeteszentrum NRW, Ruhr-Universität Bochum, 32545 Bad Oeynhausen, Germa…. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by an increased left ventricular wall thickness in the absence of increased afterload conditions. In addition to diastolic dysfunction, obstruction of the left ventricular outflow tract is common in HCM and has an important influence on symptoms and outcome. Over the last five decades or two decades, respectively, surgical myectomy and alcohol septal ablation were the only therapeutic options if standard medical care was not sufficient. Recently, a new option has become available that has the potential to revolutionize the therapeutic strategies for patients with HCM. Mavacamten is a myosin inhibitor that belongs to a completely new drug class and targets the excessive actin–myosin cross-bridging that is the underlying pathology of HCM. By reducing the actin–myosin interactions, mavacamten not only reduces the left ventricular outflow tract (LVOT) obstruction but also seems to have positive effects on the diastolic function, microcirculation, and cardiac structure. This article summarizes the current evidence on alcohol septal ablation and reviews the preclinical and clinical data on mavacamten for the treatment of patients with obstructive HCM.

Schlagwörter

Stichwörter der Autor:innen

alcohol septal ablationhypertrophic cardiomyopathyleft ventricular outflow tract obstructionmavacamtenmyosin inhibitorseptal reduction therapy

Autor:innen und Institutionen

  • Klinik für Allgemeine und Interventionelle Kardiologie/Angiologie, Herz und Diabeteszentrum NRW, Ruhr-Universität Bochum, 32545 Bad Oeynhausen, Germany.

Zitieren

APA

Scholtz, S., Rudolph, V., & Reil, J. C. (2023). Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy. Journal of Clinical Medicine, 12(20), 6628. https://doi.org/10.3390/jcm12206628

Vancouver

Scholtz S, Rudolph V, Reil JC. Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy. Journal of Clinical Medicine. 2023;12(20):6628. doi:10.3390/jcm12206628

BibTeX
@article{Scholtz2023,
  author = {Scholtz, Smita and Rudolph, Volker and Reil, Jan-Christian},
  title = {Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {20},
  pages = {6628},
  doi = {10.3390/jcm12206628}
}
Kostenlos starten →